Literature DB >> 24176266

Predicting early left ventricular dysfunction after mitral valve reconstruction: the effect of atrial fibrillation and pulmonary hypertension.

Robin Varghese1, Shinobu Itagaki2, Anelechi C Anyanwu2, Federico Milla2, David H Adams2.   

Abstract

OBJECTIVE: The preoperative ejection fraction (EF) and left ventricular (LV) end-systolic dimension are known predictors of postoperative LV dysfunction after mitral valve repair. We investigated the effect of a preoperative history of atrial fibrillation and moderate pulmonary hypertension (defined as pulmonary artery systolic pressure >50 mm Hg) on early postoperative LV dysfunction.
METHODS: From 2003 to 2010, 632 patients who had undergone successful mitral valve repair surgery for degenerative disease were included in the present study. The preoperative and postoperative echocardiographic data and postoperative outcomes were collected retrospectively. We analyzed the demographic, hemodynamic, and echocardiographic parameters to assess the predictors of early postoperative LV dysfunction, defined as an LVEF <50%.
RESULTS: The mean age of the cohort was 57 ± 13 years. All patients had less than mild mitral regurgitation on postoperative echocardiography. After mitral valve repair, a significant decrease in the LVEF (60% ± 8% to 54% ± 9%), LV end-systolic diameter (36 ± 7 mm to 33 ± 7 mm), and LV end-diastolic dimension (56 ± 8 mm to 48 ± 7 mm) was observed at early postoperative echocardiography (P < .001). On multivariate regression analysis, preoperative atrial fibrillation, pulmonary hypertension, and LV end-systolic dimension were independent predictors of the postoperative LVEF (P = .035 and P < .001, respectively). Preoperative atrial fibrillation (odds ratio, 1.97; 95% confidence interval, 1.28-3.02; P = .002) and pulmonary artery systolic pressure >50 mm Hg (odds ratio, 1.82; 95% confidence interval, 1.11-2.97; P = .017) increased the risk of postoperative LV dysfunction by almost twofold.
CONCLUSIONS: In addition to the established predictors of postoperative LV dysfunction, the presence of preoperative pulmonary hypertension and a history of atrial fibrillation in patients undergoing mitral valve repair surgery increased the risk of early postoperative LV dysfunction by almost twofold.
Copyright © 2014 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 24176266     DOI: 10.1016/j.jtcvs.2013.08.073

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  5 in total

1.  Atrial Fibrillation and Mitral Valve Prolapse: Time to Intervene?

Authors:  Michael A Borger; Moussa C Mansour; Robert A Levine
Journal:  J Am Coll Cardiol       Date:  2019-01-29       Impact factor: 24.094

2.  Risk factors of chronic left ventricular dysfunction after cardiac valve surgery.

Authors:  Xingli Fan; Yangfeng Tang; Guanxin Zhang; Jiajun Zhang; Qing Xue; Boyao Zhang; Zhiyun Xu; Lin Han
Journal:  J Thorac Dis       Date:  2020-09       Impact factor: 2.895

3.  Pulmonary artery pressure is associated with mid-term major adverse cardiovascular events and postprocedure pericardial effusion in atrial fibrillation patients undergoing left atrial appendage occlusion.

Authors:  Tian Zou; Qingxing Chen; Lei Zhang; Chaofeng Chen; Yunlong Ling; Guijian Liu; Sunying Wang; Yang Pang; Ye Xu; Kuan Cheng; Daxin Zhou; Wenqing Zhu; Junbo Ge
Journal:  Ann Transl Med       Date:  2021-08

Review 4.  Transcatheter Mitral Valve Therapy: Defining the Patient Who Will Benefit.

Authors:  Marvin H Eng; Dee Dee Wang
Journal:  Curr Cardiol Rep       Date:  2018-09-12       Impact factor: 2.931

5.  Mitral valve repair for degenerative mitral regurgitation in patients with left ventricular systolic dysfunction: early and mid-term outcomes.

Authors:  Jun Li; Yun Zhao; Tianyu Zhou; Yongshi Wang; Kai Zhu; Junyu Zhai; Yongxin Sun; Hao Lai; Chunsheng Wang
Journal:  J Cardiothorac Surg       Date:  2020-10-01       Impact factor: 1.637

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.